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Vpx is a protein encoded by members of the HIV-2/SIVsmm and SIVrcm/SIVmnd-2
lineages of primate lentiviruses, and is packaged into viral particles. Vpx plays a critical role
during the early steps of the viral life cycle and has been shown to counteract SAMHD1, a
restriction factor in myeloid and resting T cells. However, it is becoming evident that Vpx is
a multifunctional protein in that SAMHD1 antagonism is likely not its sole role. This review
summarizes the current knowledge on this X-traordinary protein.
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Vpx was initially identified as an HIV-2 (human immunodefi-
ciency virus type 2)/SIVsmm (simian immunodeficiency virus
infecting sooty mangabey monkey) protein of 12–16 kDa, which
is incorporated into viral particles (Franchini et al., 1988;
Henderson et al., 1988; Kappes et al., 1988; Yu et al., 1988). In
addition to viruses from the HIV-2/SIVsmm lineage of primate
lentiviruses, this gene is also found in viruses from the SIVrcm
(infecting red-capped mangebey)/SIVmnd-2 (infecting mandrill)
lineage (Beer et al., 2001; Hu et al., 2003). It is homologous
to the vpr gene, found in every lineage of primate lentiviruses
(Tristem et al., 1990). Vpx was rapidly shown to be dispensable
for viral replication in immortalized lymphocytic cell lines, such
as HUT78, CEM, or SupT1 (Yu et al., 1988; Guyader et al., 1989;
Hu et al., 1989; Shibata et al., 1990; Gibbs et al., 1994; Park and
Sodroski, 1995), and in the monocytic cell lines HL60 and U937
(Guyader et al., 1989; Hu et al., 1989). In contrast, vpx deletion led
to a strong replication defect in monocyte-derived macrophages
(MDMs) (Yu et al., 1991; Gibbs et al., 1994; Park and Sodroski,
1995; Fletcher et al., 1996; Ueno et al., 2003). In addition, vpx
deletion led to SIVmac (infecting rhesus monkey) and HIV-2
replication defects in activated peripheral blood mononuclear
cells (PBMCs) or primary T cells, especially at low viral inputs
(Guyader et al., 1989; Kappes et al., 1991; Yu et al., 1991; Akari
et al., 1992; Gibbs et al., 1994; Kawamura et al., 1994; Park and
Sodroski, 1995; Ueno et al., 2003). Vpx was shown to be impor-
tant for HIV-2 replication in HSC-F cells, a simian lymphocytic
cell line (Ueno et al., 2003). Vpx is packaged into viral particles via
an interaction with the p6 domain of Gag (Wu et al., 1994; Accola
et al., 1999; Selig et al., 1999) and is associated with mature viral
cores (Kewalramani and Emerman, 1996). This suggested that
Vpx could participate in the early steps of infection. Comparisons
of virus associated proteins suggested that Vpx from SIVmac and
HIV-2 are packaged in equimolar amounts to Gag (Henderson
et al., 1988), although the exact number of molecules packaged
per virion has not been determined.
Vpx localizes to the nucleus in transfected cells (Depienne
et al., 2000; Mahalingam et al., 2001; Belshan and Ratner, 2003),
and this is conferred by a C-terminal non-canonical nuclear local-
ization signal (NLS) (65-SYTKYRYL-72) (Figure 1) (Belshan and
Ratner, 2003; Rajendra Kumar et al., 2003), as well as a poten-
tial second N-terminal NLS (Singhal et al., 2006a). Whether Vpx
shuttles between the cytoplasm and nucleus due to a nuclear
export signal remains controversial (Belshan and Ratner, 2003;
Singhal et al., 2006b). Likewise Vpx phosphorylation has been
proposed to regulate its nuclear import (Rajendra Kumar et al.,
2005) but other studies failed to detect this post-translational
modification (Franchini et al., 1988; Belshan et al., 2006). By
virtue of its karyophilic properties, Vpx was proposed to play
a critical role in the nuclear import of viral reverse transcrip-
tion complexes in non-dividing cells, such as MDMs and arrested
U937 cells (Pancio et al., 2000; Mahalingam et al., 2001; Rajendra
Kumar et al., 2003). Indeed the replication defect of viruses lack-
ing Vpx (or bearing non-karyophilic mutated versions of Vpx)
correlated with the absence of 2-LTR circles (a surrogate marker
for viral DNA nuclear entry) (Fletcher et al., 1996; Pancio et al.,
2000; Ueno et al., 2003; Belshan et al., 2006).
Later studies using lentiviral vectors and single-round infec-
tions confirmed a cell-type dependent effect of Vpx and a role
in the early events of infection. Vpx is essential for transduc-
tion of monocyte-derived dendritic cells (MDDCs) with SIVmac
based-lentiviral vectors (Mangeot et al., 2002). Surprisingly, when
brought in trans via virus-like particles (VLPs), Vpx increases
HIV-1 transduction of MDDCs and MDMs but not activated
T cells (Goujon et al., 2006). This positive effect of Vpx in
MDDCs was directly correlated with an increase in viral DNA
accumulation, which was observed not only with SIVmac but
also with heterologous retroviral vectors, derived from HIV-1,
feline immunodeficiency virus (FIV) and murine leukemia virus
(MLV) (Goujon et al., 2007). Of note, in the case of MLV, Vpx
rescued viral DNA accumulation but not 2-LTR circle formation
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FIGURE 1 | HIV-2 ROD, SIVmac, and SIVrcm Vpx aminoacid sequence alignment.
(Goujon et al., 2007; Gramberg et al., 2013), consistent with a
nuclear-entry block to MLV infection in non-dividing cells (Roe
et al., 1993; Lewis and Emerman, 1994). Vpx was later shown to
favor HIV-2/SIVsmmDNA accumulation in MDMs (Fujita et al.,
2008; Srivastava et al., 2008; Bergamaschi et al., 2009).
Animal studies showed that Vpx is crucial for SIVsmmPBj and
SIVmne (infecting pig-tailed macaque) replication and spread in
a pig-tailed macaque model. SIVsmm PBj vpxmutant virus repli-
cated to a considerably lower extent and showed much reduced
kinetics as compared to wild-type virus (Hirsch et al., 1998). In
addition, the mutant virus was outcompeted when inoculated
together with wild-type SIVsmm PBj (Hirsch et al., 1998). In
vitro, SIVmne vpx mutants infected pig-tailed macaque PBMCs
to comparable levels to that of wild-type virus, but showed sig-
nificantly reduced infectivity in MDMs (Belshan et al., 2012).
Another study reported a less prominent effect of Vpx in rhe-
sus monkeys infected with SIVmac239, with delayed viral kinetics
for vpx deficient virus but AIDS development nonetheless (Gibbs
et al., 1995).
The fact that Vpx could act in trans on other retroviruses
strongly suggested at the time that Vpx modulates the cellular
environment to increase cell permissivity to infection, possibly by
preventing the action of an inhibitory factor. The first evidence
of the existence of such a dominant inhibitory factor in myeloid
cells came from the use of heterokaryons generated between
permissive (COS) cells and restrictive cells (MDMs) (Sharova
et al., 2008). Unlike COS cells, both MDMs and COS-MDMs
heterokaryons restricted SIVsmm PBj in the absence of Vpx at
the level of viral DNA accumulation. The same authors also
observed a dominant restriction phenotype in heterokaryons
formed between primary monocytes and HeLa cells (Kaushik
et al., 2009).
HIJACKING THE DCAF1/DDB1/CUL4A E3 UBIQUITIN LIGASE
In parallel with the aforementioned viral and cell biology exper-
iments, proteomic studies yielded some fundamental insights.
Initially, Le Rouzic et al. discovered that HIV-1Vpr recruits
the damage-specific DNA binding protein 1 (DDB1)-Cullin
4A (CUL4A) E3 ubiquitin ligase complex through the binding
of a known interactor of Vpr, VprBP (Zhao et al., 1994; Le
Rouzic et al., 2007). VprBP had previously been identified in
a screen as the substrate recruiting module of DDB1-CUL4A-
RBX1/ROC1 complexes, and renamed DDB1-CUL4A-associated
factor 1 (DCAF1) (Angers et al., 2006). Using yeast two-hybrid,
Le Rouzic et al. also showed that Vpx from SIVmac, similarly
to HIV-1Vpr, was able to bind VprBP/DCAF1 (Le Rouzic et al.,
2007). This interaction was soon confirmed in mammalian cells
(Goujon et al., 2008; Sharova et al., 2008; Srivastava et al., 2008;
Bergamaschi et al., 2009). RNAi-mediated depletion of DCAF1
or DDB1 profoundly reduced SIVmac as well as HIV-2 infec-
tion of macrophages (Sharova et al., 2008; Srivastava et al., 2008;
Bergamaschi et al., 2009). This invoked amodel by which Vpx was
hijacking a DCAF1-DDB1-CUL4A E3 ubiquitin ligase to induce
the degradation of a myeloid cell specific restriction factor that
prevents viral DNA accumulation (Sharova et al., 2008; Srivastava
et al., 2008; Bergamaschi et al., 2009).
SAMHD1 ANTAGONISM
To isolate the cellular factor(s) limiting HIV-1 infection in
myeloid cells, the groups of Monsef Benkirane and Jacek
Skowronski exploited similar proteomic approaches, using tan-
dem affinity purification combined with mass spectrometry to
identify Vpx binding partners (Hrecka et al., 2011; Laguette
et al., 2011). Both labs identified sterile alpha motif (SAM)
and HD-domain-containing protein 1 (SAMHD1) as one of the
major binding partners of SIVmac Vpx. SAMHD1 silencing phe-
nocopied the effect of Vpx-containing VLPs in that it rescued
HIV-1 infection of both differentiated THP-1 monocytic cells
and MDDCs (Laguette et al., 2011). Both studies showed that
HIV-2/SIVmac Vpx induced SAMHD1 proteasomal degradation
(Hrecka et al., 2011; Laguette et al., 2011). Importantly, SAMHD1
antagonism is a function conserved in all clades of Vpx proteins,
in a species specific way (Lim et al., 2012). In certain SIVs devoid
of a Vpx protein, Vpr can antagonize SAMHD1. For instance,
Vpr from SIVdebCM5 (infecting De Brazza’s monkeys), SIVagm
(African green monkeys), and SIVmus1 (mustached monkeys)
can degrade SAMHD1 of their natural host when expressed in
human cells, whereas Vpr from HIV-1 and SIVcpz (chimpanzee)
cannot (Lim et al., 2012).
SAMHD1 is a 626 amino acid protein that consists of an
amino-terminal SAM domain, a central HD domain and a
C-terminal uncharacterized domain (Li et al., 2000; Liao et al.,
2008). SAMHD1 is a deoxynucleoside-triphosphate (dNTP)
phosphohydrolase (Goldstone et al., 2011; Powell et al., 2011;
Yan et al., 2013), which reduces the pool of dNTPs available for
reverse transcription both in myeloid cells (Lahouassa et al., 2012;
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St Gelais et al., 2012) and in resting T cells (Baldauf et al., 2012;
Descours et al., 2012). These observations therefore explain why
the provision of exogenous deoxyribonucleosides (dN) to resting
T cells, which have long been known to restrict lentiviral infec-
tion at several steps of the life cycle (Pan et al., 2013), increases
the accumulation of viral DNA (Korin and Zack, 1999).
Crosslinking experiments show that SAMHD1 forms
oligomers in cells and it has been proposed that the enzymatically
active form of SAMHD1 is a tetramer and that tetramerization is
driven by dGTP binding to the allosteric sites (Ji et al., 2013; Yan
et al., 2013). Knock-out mice analysis have recently confirmed
that SAMHD1 functions as a dNTPase in vivo as these mice show
elevated levels of intracellular dNTPs in DCs isolated from bone
marrow (Behrendt et al., 2013; Rehwinkel et al., 2013). Therefore,
SAMHD1 reduces cellular dNTP levels and this impacts reverse
transcription most significantly in situations where dNTP levels
are naturally lower, such as post-mitotic or non-dividing cells.
Mutations in SAMHD1 are associated with the genetic
neurodegenerative disorder Aicardi-Goutières syndrome (AGS),
which is characterized by the excessive production of type 1
interferon (IFN) in the cerebrospinal fluid and resembles congen-
ital infection (Rice et al., 2009; Chahwan and Chahwan, 2012).
Interestingly, CD14+ cells from AGS patients with mutations in
SAMHD1 are more susceptible to HIV-1 infection than cells from
healthy controls (Berger et al., 2011a). This shows the impor-
tance of SAMHD1 for preventing HIV-1 infection in monocytes,
well known to be naturally refractory to HIV-1 infection in vitro
(Sonza et al., 1996; Neil et al., 2001; Triques and Stevenson, 2004).
In addition to a variety of retroviruses (Gramberg et al., 2013;
Sze et al., 2013), SAMHD1 blocks replication of DNA viruses,
such as vaccinia virus and herpex simplex virus 1 (Hollenbaugh
et al., 2013; Kim et al., 2013). SAMHD1 is also active against
retroelements (Zhao et al., 2013), suggesting that increased retro-
transposition might be leading to immune sensing of DNA and
activation of signaling pathways in AGS patients with SAMHD1
mutations, as proposed for the 3′-5′ exonuclease TREX1 (three
prime repair exonuclease) (Stetson et al., 2008; Beck-Engeser
et al., 2011). Indeed, mutations in TREX1 can cause AGS (Crow
et al., 2006) and in Trex1-deficient mice, reverse transcribed DNA
from endogenous retroelements accumulated and stimulated
intrinsic immune responses (Stetson et al., 2008). Interestingly,
Zhao et al. showed that both endogenous and overexpressed
SAMHD1 prevented LINE-1 (long interspersed element-1) retro-
transposition in 293T cells (Zhao et al., 2013). This effect of
SAMHD1 on retrotransposition was not dependent on its cat-
alytic activity and was counteracted by Vpx. Therefore, infection
by lentiviruses encoding a SAMHD1 antagonist (either Vpx or
Vpr) might lead to increased replication of endogenous retroele-
ments and a possible impact on host genome stability.
SAMHD1 is expressed at similar levels in MDMs, resting
CD4+ T cells and in activated CD4+ T cells (Baldauf et al., 2012;
Descours et al., 2012), but does not block HIV-1 infection in
the latter. The discrepancy of SAMHD1’s antiviral function in
cycling vs. non-cycling cells led several groups to investigate cell
cycle dependent determinants for both the antiviral and dNTPase
activities of SAMHD1. SAMHD1 was found to interact with and
be phosphorylated by the cell cycle regulator cyclin-dependent
kinase 1 (CDK1) in proliferating cells, and phosphorylation at
the residue T592 has been shown to prevent lentiviral restriction
(Cribier et al., 2013; White et al., 2013). CDK1 is inactive in rest-
ing cells, suggesting that the cell cycle progression correlates with
SAMHD1’s antiviral activity. In line with this, a phosphorylation-
defective mutant of SAMHD1 was antiviral both in resting and
in dividing U937 cells (Cribier et al., 2013). In addition, the
phosphomimetic SAMHD1 mutant T592E was unable to restrict
HIV-1 infection (Welbourn et al., 2013; White et al., 2013).
However, phosphorylation did not affect the ability of SAMHD1
to hydrolyse dNTPs in an in vitro dNTPase assay (Welbourn et al.,
2013) or in differentiated U937 monocytic cells (White et al.,
2013). Although phosphorylated and lacking antiviral activity
in cycling cells, SAMHD1’s role in dNTP metabolism in these
cells remains unclear. Cycling cells contain high levels of dNTPs
(Diamond et al., 2004), therefore de novo dNTP synthesis likely
compensates for any potential effect of SAMHD1. The fact that
SAMHD1 mutant T592E lacks antiviral activity while being an
active dNTPase suggests the existence of a potential dNTPase-
independent restriction mechanism. Supporting the notion that
SAMHD1’s influence on infection may be more complex, it has
been suggested that SAMHD1 interacts with nucleic acids, specif-
ically ssRNA and ssDNA (Goncalves et al., 2012; Tungler et al.,
2013) and that it possesses a nuclease activity (Beloglazova et al.,
2013).
SAMHD1 is localized in the nucleus of differentiated cells.
However, disruption of its NLS does not affect antiviral activ-
ity (Rice et al., 2009; Brandariz-Nunez et al., 2012; Hofmann
et al., 2012), yet results in a relative resistance to SIVmac Vpx-
mediated degradation (Brandariz-Nunez et al., 2012; Hofmann
et al., 2012; Wei et al., 2012; Guo et al., 2013). Given that Vpx
efficiently interacts with both nuclear and cytoplasmic SAMHD1
(Hofmann et al., 2012), it is difficult to understand why cytoplas-
mic SAMHD1 is less sensitive to Vpx-induced degradation. It is
possible for example that factors of the DCAF1-DDB1-CUL4A
E3 ubiquitin ligase machinery are limiting in the cytoplasm,
or that differences in SAMHD1’s post-translational modifica-
tions prevent cytoplasmic SAMHD1 degradation. Alternatively
there might be differences in ubiquitination or deubiquitination
processes between nuclear and cytoplasmic SAMHD1.
Intriguingly, in contrast to what is observed in MDDCs, wild-
type SAMHD1 from myeloid and plasmacytoid DCs (mDCs and
pDCs, respectively), was shown to be resistant to Vpx-induced
degradation (Bloch et al., 2014). The sensitivity to Vpx-induced
degradation of SAMHD1 as well as the Vpx effect on HIV-1
infectivity could be partially restored by blocking IFN signaling
using neutralizing antibodies (Bloch et al., 2014). This suggests
that IFN-induced factors might prevent SAMHD1 degradation
in mDCs and pDCs or that SAMHD1 localization might be
modified following IFN exposure, rendering it resistant to Vpx-
mediated degradation. In line with this, Dragin et al. observed
a reduced sensitivity of SAMHD1 to Vpx-mediated degradation
in IFN-treated THP-1, suggesting that IFN-stimulated genes may
participate in this process (Dragin et al., 2013). In addition, IFN
treatment did not modify SAMHD1 localization (Dragin et al.,
2013). In contrast, we have observed an efficient degradation of
SAMHD1 in IFN-treated THP-1 cells (Goujon et al., 2013), but
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the reasons for these differences are currently unknown. Type
1 IFN treatment reduced SAMHD1 phosphorylation levels of
residue T592 in MDMs and MDDCs, suggesting the existence
of IFN-inducible phosphatase(s) activating SAMHD1 (Cribier
et al., 2013). The identification of this/these phosphatase(s) would
improve our understanding of the regulation of SAMHD1’s
antiviral activity.
STRUCTURAL INSIGHTS
Vpx recruits the DCAF1-DDB1-CUL4A E3 ubiquitin ligase
complex to induce SAMHD1’s proteasomal degradation via
an interaction with its C-terminal domain (Ahn et al., 2012)
(Figure 2). The crystal structure of a complex between SIVsmm
Vpx, the C-terminal domain of the ubiquitin-ligase adaptor
DCAF1 (DCAF1-CtD) and the Vpx-binding, C-terminal domain
of SAMHD1 (SAMHD1-CtD, residues 582-626) was revealed
recently (Figure 3) (Schwefel et al., 2014). This structure shows
that Vpx is composed of a three-helix bundle stabilized by
a zinc finger motif (formed of residues H39, H82, C87 and
C89) (Figure 4A) and extensively interacts with DCAF1-CtD
(Figure 4B), the latter forming a seven-bladed β-propeller disc-
shaped molecule. Both proteins offer a shared interface used to
bind SAMHD1-CtD. A model of the hijacked DCAF1-DDB1-
CUL4A complex in association with the RBX1 RING module
(RING-box protein 1), generated using previously determined
structures, clearly showed that SAMHD1 is positioned in the
vicinity of the RBX1 RING module, allowing accessibility to
ubiquitination (Schwefel et al., 2014) (Figure 2). The SAMHD1
target sites for Vpx-induced ubiquitination have not been deter-
mined yet. In addition to ubiquitination, neddylation is required
for SAMHD1 degradation, consistent with the importance of
NEDD8 transfer to CUL4A through UBC12 (Hofmann et al.,
2013). It would be of interest to understand the structural con-
sequences of Vpx interaction with tetrameric SAMHD1. There
is some evidence from surface plasmon resonance experiments
that Vpx interaction with SAMHD1 causes the disassembly of
enzymatically active SAMHD1 oligomers and interferes with
SAMHD1 enzymatic activity prior to its degradation (Delucia
et al., 2013). This suggests a model where proteasomal degra-
dation may be the consequence and not the initiating event in
Vpx-mediated SAMHD1 antagonism.
Extensive mutagenesis of Vpx has shed light into the criti-
cal residues of Vpx (Table 1 and Figure 4). Notably, N-terminal
Vpx amino acids are essential to rescue virus infectivity in
myeloid cells and SAMHD1 degradation (Goujon et al., 2008;
Gramberg et al., 2010; Ahn et al., 2012; Fregoso et al., 2013). Of
major interest, the phenotypes of some well characterized Vpx
mutants are explained by the structure (Schwefel et al., 2014).
For instance, the Vpx Q76A mutant is unable to bind DCAF1
and degrade SAMHD1 (Srivastava et al., 2008; Bergamaschi et al.,
2009; Hrecka et al., 2011). The structure shows that this defect
may be due to disrupted hydrogen bonds between Q76 and
residues N1135 and W1156 of DCAF1 (Figure 4B) (Schwefel
et al., 2014). Similarly, residue K77, critical for DCAF1 bind-
ing and Vpx activity (Bergamaschi et al., 2009), is integral to an
extensive salt-bridge network that links residues E1091-D1092-
E1093 of DCAF1 with residues R70, Y69 and Y66 in helix 3 of
FIGURE 2 | Model of DCAF1-DDB1-CUL4A recruitment by Vpx. Vpx
hijacks the DDB1-CUL4A-RBX1 E3 ubiquitin ligase complex through
recruitment of DCAF1 (also known as VprBP). Vpx targets (i.e., SAMHD1
and possibly unknown proteins) are ubiquitinated through the activity of
RBX1 and an E2 ligase that interacts with RBX1. In addition, RBX1 interacts
with the ubiquitin-conjugating enzyme UBC12, which is important for
neddylation of CUL4A through transfer of the NEDD8 group from NEDD8
activating enzyme (NAE).
Vpx (Figure 4B). In addition, Vpx W24A mutant was shown
to have lost SAMHD1 antagonism while being able to bind to
DCAF1 (Wei et al., 2012). This phenotype is explained by a
stacking between residues W24 of Vpx and R617 of SAMHD1
(Figure 4C) (Schwefel et al., 2014). In line with this, SAMHD1
R617 mutants completely lost sensitivity to Vpx-mediated degra-
dation while maintaining antiviral activity (Schwefel et al.,
2014).
ADDITIONAL ROLES OF Vpx?
The fact that vpx deletion leads to some replication defects in
activated PBMCs or primary T cells (Guyader et al., 1989; Kappes
et al., 1991; Yu et al., 1991; Akari et al., 1992; Gibbs et al., 1994;
Kawamura et al., 1994; Park and Sodroski, 1995; Ueno et al., 2003)
strongly suggests that Vpx might have other functions beyond
counteracting SAMHD1, which is only relevant in myeloid and
resting T cells. As mentioned above, it has been proposed that
Vpx participates in the nuclear import of viral reverse transcrip-
tion complexes (Fletcher et al., 1996; Pancio et al., 2000; Ueno
et al., 2003; Belshan et al., 2006). Possibly in favor of such an addi-
tional role of Vpx, someVpxmutants have amore profound effect
on MDDCs transduction with SIVmac lentiviral vectors than
with HIV-1 (e.g., T17A, T28A, or GC86,87A Vpx mutants which
fail to rescue SIVmac infection but improve HIV-1 infection by
more than one order of magnitude Goujon et al., 2008; Table 1).
Moreover, a Vpx mutant devoid of the C-terminus proline-rich
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FIGURE 3 | Vpx/SAMHD1 CtD/DCAF1 CtD complex structure. Shown is the co-crystal structure of DCAF1 CtD (brown) with SAMHD1 CtD (green) in
complex with Vpx from SIVsmm (dark red) (Schwefel et al., 2014) (PDB:4CC9) from three different sites. The zinc ion coordinated by Vpx is shown in red.
FIGURE 4 | Vpx structure. (A) Depicted is the structure of Vpx from
SIVsmm as obtained in the co-crystallization with the C-terminus of
DCAF1 and the C-terminus of SAMHD1 (both not shown) with critical
amino acids highlighted (PDB:4CC9) (Schwefel et al., 2014). SIVsmm
Vpx comprises an anti-parallel bundle of three helices, resembling the
shape of a V. Vpx coordinates a zinc ion (red) with amino acids H39,
H82, C87, and C89. The structure between Vpx residues 90–100 is
absent (dashed gray line). (B) Critical aminoacid residues in the
interface between DCAF1 and Vpx are highlighted. Vpx Q76 residue
(cyan) may form hydrogen bonds with N1135 and W1156 residues (lilac)
of DCAF1. The acidic region in DCAF1 comprising E1091, D1092 and
E1093 residues (yellow) may interact with positively charged K77
residue (purple) of Vpx. (C) Critical amino acid residues for the
interaction of SAMHD1 and Vpx are highlighted. SAMHD1 R617 residue
(light green) stacks with the indole ring of Vpx W24 residue (orange).
Vpx Y66 and Y69 residues (fluorescent green) are in close proximity to
SAMHD1 K622 and V618 residues (light green), the latter being
positively selected (Laguette et al., 2012).
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Table 1 | Phenotype of Vpx mutants.
Mutant Virus Phenotype References
N12A SIVmac No infection rescue of HIV-1 in MDMs
Partial SAMHD1 degradation
Gramberg et al., 2010; Ahn et al., 2012
S13A SIVmac Rescue SIVmac and HIV-1 in MDMs and MDDCs
SAMHD1 degradation
Goujon et al., 2008; Gramberg et al.,
2010; Berger et al., 2012
E15A SIVmac No rescue of HIV-1 in MDMs
Partial SAMHD1 degradation
Gramberg et al., 2010; Ahn et al., 2012
E16A SIVmac No rescue of HIV-1 in MDMs
Partial SAMHD1 degradation
Gramberg et al., 2010; Ahn et al., 2012
T17A SIVmac No rescue of SIVmac in MDDCs but partial activity on HIV-1, no
rescue in MDMs
Partial SAMHD1 degradation
Goujon et al., 2008; Gramberg et al.,
2010; Ahn et al., 2012
E20A SIVmac Rescue of HIV-1 in MDMs Gramberg et al., 2010
W24A SIVmac No infection rescue, interaction with DCAF1 Wei et al., 2012
N26A SIVmac Rescue of SIVmac and HIV-1 in MDDCs Goujon et al., 2008
R27A SIVmac Rescue of HIV-1 in MDMs Gramberg et al., 2010
T28A SIVmac No rescue of SIVmac in MDDCs but partial activity on HIV-1 Goujon et al., 2008
V29S SIVmac Reduced interaction with DCAF1
Interaction with SAMHD1 but no degradation, no infection rescue
Wei et al., 2012
STT13,17,28A SIVmac No infection rescue in MDDCs with SIVmac or HIV-1, no SAMHD1
degradation
Goujon et al., 2008
I32S SIVmac No infection rescue, no interaction with DCAF1, no degradation of
SAMHD1
Wei et al., 2012
H39A SIVmac, HIV-2
GH-1
No infection rescue, no interaction with DCAF1, no degradation of
SAMHD1
Goujon et al., 2008; Wei et al., 2012
W49,53,56A SIVmac No infection rescue in MDDCs with SIVmac or HIV-1
No degradation of SAMHD1
Goujon et al., 2008; Berger et al., 2012
S52A SIVmac
HIV-2 GH-1
Infection rescue in MDDCs with SIV or HIV-1, HIV-2GL-AN
replication in MDDCs
SAMHD1 degradation
Goujon et al., 2008; Berger et al., 2012
S63,65A SIVmac Infection rescue in MDDCs with SIV or HIV-1 Goujon et al., 2008
KK84,85A SIVmac, HIV-2
GH-1
Infection rescue in MDDCs with HIV-1, SAMHD1 degradation
Slightly reduced activity for SIVmac and HIV-2GL-AN replication in
MDDCs
Goujon et al., 2008; Berger et al., 2012
KK84,85R SIVsm PBj1.9 Defect in DNA accumulation in MDMs Sharova et al., 2008
K77A SIVsmPBj No infection rescue, no interaction with DCAF1 Bergamaschi et al., 2009
KK68,77A or R SIVmac
SIVsm PBj1.9
No infection rescue in MDDCs or MDMs infection with SIVmac,
SIVSM PBj1.9 or HIV-1
No degradation of SAMHD1
Goujon et al., 2008; Sharova et al.,
2008; Berger et al., 2012
KKKR68,77,84,85A
or R
HIV-2 GH-1,
SIVsm PBj1.9
No infection of MDMs, no replication of HIV-2 GL-AN in MDDCs Goujon et al., 2008; Sharova et al.,
2008
Y66,69,71A SIVmac, SIVmne No infection rescue, no interaction with DCAF1, no degradation of
SAMHD1
Goujon et al., 2008; Belshan et al.,
2012; Berger et al., 2012
Q76A or R SIVmac, HIV-2
ROD, HIV-2
GH-1
No infection rescue, no interaction with DCAF1, no degradation of
SAMHD1
BUT rescue of HIV-1 from IFN block
Srivastava et al., 2008; Hrecka et al.,
2011; Berger et al., 2012
Bergamaschi et al., 2009; Laguette
et al., 2011; Pertel et al., 2011
Wei et al., 2012
F80A SIVmac No infection rescue, no interaction with DCAF1, no degradation of
SAMHD1
BUT rescue of HIV-1 from IFN block
Srivastava et al., 2008; Laguette et al.,
2011; Pertel et al., 2011
GC86,87A SIVmac No rescue of MDDCs infection with SIVmac but partial activity on
HIV-1
Goujon et al., 2008
Pro SIVmac, HIV-2
GH-1, HIV-2
ROD
Rescue of HIV-1 infection, slight activity loss on SIVmac, SAMHD1
degradation
No replication of HIV-2GL-AN or HIV-2rod in MDDCs and MDMs
Pancio et al., 2000; Goujon et al.,
2008; Berger et al., 2012
Non-exhaustive list of characterized Vpx mutants, summarizing their activity either in single-cycle infection with SIVmac and HIV-1 or in replication (in MDMs and/or
MDDCs), and their ability to interact with DCAF1 and SAMHD1, and to degrade the latter.
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region is still able to efficiently degrade SAMHD1 and to res-
cue HIV-1 in single-cycle infection of MDDCs (Goujon et al.,
2008; Berger et al., 2012), but does not support HIV-2 replica-
tion in MDMs or MDDCs (Pancio et al., 2000; Goujon et al.,
2008). Finally, Vpx was proposed to increase HIV-1 infectivity in
a DCAF1-independent way both in IFN-treated MDDCs and in
THP-1 cells, suggesting additional function(s) beyond SAMHD1
degradation (Goujon et al., 2008; Pertel et al., 2011; Reinhard
et al., 2014).
APOBEC3A ANTAGONISM?
In addition to the well-documented interaction with SAMHD1,
Vpx interacts with a member of the apolipoprotein B mRNA-
editing enzyme catalytic polypeptide-like 3 (APOBEC3) family
of cytidine deaminases, namely APOBEC3A. APOBEC3 fam-
ily members, exemplified by APOBEC3G, are potent restriction
factors (reviewed in Malim and Bieniasz, 2012). HIV-1 pre-
vents APOBEC3G/F/D/H action through proteasomal degrada-
tion induced by the Vif accessory protein. APOBEC3A affects
various viruses and retroelements, such as human papilloma virus
(Vartanian et al., 2008), adeno-associated virus (AAV) (Chen
et al., 2006), and retrotransposons (Bogerd et al., 2006; Chen
et al., 2006; Muckenfuss et al., 2006). Interestingly, APOBEC3A
expression levels have been linked to myeloid cell restric-
tion of HIV-1 infection (Peng et al., 2007). In line with this,
APOBEC3A silencing increased the ability of HIV-1 to repli-
cate in MDMs (Peng et al., 2007; Berger et al., 2011b). Two
independent groups have shown that HIV-2/SIVsmm Vpx inter-
acts with human APOBEC3A using co-immunoprecipitation of
overexpressed proteins (Berger et al., 2010, 2011b). Both groups
reported a decreased stability of APOBEC3A in the presence
of Vpx. Similarly, wild-type SIVsmm replication led to slightly
decreased APOBEC3A expression levels in monocytes compared
to Vpx-deficient viruses (Berger et al., 2010). These data led to
the hypothesis that Vpx might enhance infection of myeloid cells
by inducing APOBEC3A degradation. However, the precise con-
tribution of APOBEC3A to the resistance of HIV-1 infection in
myeloid cells is difficult to evaluate, as SAMHD1 imposes a strong
barrier to infection in these cells and is counteracted by Vpx. It
would be crucial to separate, if possible, the two activities of Vpx,
for instance by identifying mutants of Vpx retaining the ability
of interacting with APOBEC3A but not SAMHD1 (or vice versa),
and evaluating their effect in myeloid cells.
ANTAGONISM OF INTERFERON-INDUCED FACTOR(S)?
It has been known for decades that type 1 IFN treatment potently
decreases HIV-1 infection in some immortalized cell lines and
in primary cells, such as MDMs and MDDCs (Kornbluth et al.,
1989; Shirazi and Pitha, 1992; Baca-Regen et al., 1994; Cheney
and McKnight, 2010; Goujon and Malim, 2010). Interestingly,
this IFN-induced block is primarily exerted at the level of viral
DNA accumulation (Shirazi and Pitha, 1993; Baca-Regen et al.,
1994; Cheney and McKnight, 2010; Goujon and Malim, 2010),
which is exactly the step at which SAMHD1 acts (Hrecka et al.,
2011; Laguette et al., 2011). Strikingly, Vpx is still capable of
enhancing HIV-1 infection in IFN-treated myeloid cells and the
magnitude of the infectivity enhancement is increased in this
context (Gramberg et al., 2010; Pertel et al., 2011; Goujon et al.,
2013). SAMHD1 was reported to be IFN-inducible in some cell
types, such as primary monocytes (Berger et al., 2011a). This
suggested that SAMHD1 might be playing a role in the IFN
block to HIV-1 infection. But neither SAMHD1 expression nor
dNTP intracellular concentrations seem to be regulated by IFN
treatment in MDMs or MDDCs (St Gelais et al., 2012; Dragin
et al., 2013; Goujon et al., 2013). Furthermore, RNAi-mediated
SAMHD1 silencing fails to rescue myeloid cell infection in the
presence of IFN (Dragin et al., 2013; Goujon et al., 2013). In
addition, Q76A Vpx mutant was still able to substantially res-
cue IFN-treated MDDC infection (Pertel et al., 2011; Reinhard
et al., 2014), although it was unable to bind DCAF1 (Pertel et al.,
2011) and induce SAMHD1 degradation (Hrecka et al., 2011).
Whereas exogenous dN and SIVmac Vpx increased the accumu-
lation of HIV-1 late reverse transcription products to the same
extent in IFN-treated myeloid cells, Vpx had a higher impact
on 2-LTR circle and proviral DNA formation (Reinhard et al.,
2014). This feature was not observed with SIVmus and SIVdeb
Vpr, despite their ability to degrade human SAMHD1 (Reinhard
et al., 2014). Taken together, these data strongly suggest that
HIV-2/SIVmac Vpx may be counteracting other myeloid specific,
IFN-inducible anti-HIV-1 factor(s). It could be tempting to spec-
ulate that APOBEC3A may be one of these. Indeed, APOBEC3A
is highly induced by IFN treatment in myeloid cells (Peng et al.,
2006; Koning et al., 2009; Refsland et al., 2010) and Vpx is
known to interact with APOBEC3A (Berger et al., 2010, 2011b).
However, APOBEC3A was not degraded in the presence of Vpx-
VLPs following IFN treatment, contrary to SAMHD1, which is
potently and rapidly degraded (Dragin et al., 2013). It remains
possible that APOBEC3A is sequestered by Vpx rather than
degraded in these conditions. Single-genome sequencing of viral
DNA following HIV-1 infection of IFN-treated MDMs showed
only infrequent editing and no sign of hypermutation, arguing
against a major role for APOBEC3 proteins in the IFN block
(Koning et al., 2011), though this does not exclude a deamination-
independentmechanism. Indeed, APOBEC3A is known to inhibit
AAV via a deamination-independent mechanism (Narvaiza et al.,
2009). Further work will be required to address the exact role of
APOBEC3A in the IFN-induced block to HIV-1 infection, and to
determine whether Vpx is counteracting additional IFN-induced
anti-HIV-1 factors in myeloid cells. Of note, SIVmac lentiviral
vectors are still sensitive to the antiviral action of IFN in human
primary cells despite the presence of Vpx (Goujon and Malim,
2010; Reinhard et al., 2014). This may reflect the existence of
species-specific IFN-induced genes to which SIVmac is sensitive
in human cells contrary to HIV-1, and which are not counteracted
by Vpx (Bitzegeio et al., 2013; Cordeil et al., 2013).
ORIGIN AND EVOLUTION OF vpx
The HIV-2/SIVsmm and SIVrcm/SIVmnd-2 lineages possess 2
homologous genes to HIV-1/SIVcpz vpr: vpr and vpx. The vpr
and vpx genes are paralogs and are the result of complex
duplication and/or recombination of their precursor through-
out the diversification of primate lentiviruses. vpr has most
likely diverged through cross-species transmission, rather than
co-evolution with their hosts following ancient infection. To
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illustrate this, Wertheim and Worobey studied mitochondrial
sequences of several species of the African green monkey lin-
eage and their SIVagm and have rejected the hypothesis of co-
divergence between SIVagm and its host. Their data support the
hypothesis of a host-switching model following a geographical
pattern of transmission (Wertheim and Worobey, 2007). Whilst
vpr is found in all lentiviral groups, vpx is found only in two
lineages: HIV-2/SIVsmm/SIVmac and SIVrcm/SIVmnd-2 (Beer
et al., 2001; Hu et al., 2003). These viruses infect sootymangabeys,
macaques, mandrills and red-capped mangabeys, all of which
belong to the same primate family.
The vpx genes from the SIVrcm/SIVmnd-2 lineage are quite
divergent from other vpx genes (only about 30–40% iden-
tity at the amino acid level with Vpx from HIV-2/SIVsmm).
Nonetheless, the monophyletic nature of the vpx clade supports
the hypothesis of a single event leading to the birth of vpx, rather
than multiple events (Hu et al., 2003).
Two hypotheses have been proposed so far to explain the birth
of vpx. It has first been suggested that vpx arose by duplication
of the vpr ancestor (Tristem et al., 1990). This was supported by
sequence similarity and by the fact that both genes are always
adjacent to each other in the genome. Alternatively, because
vpx genes are closely related to vpr from SIVagm.Sab (infect-
ing African green monkeys) (Figure 5), it has been proposed by
another group that a recombination event between SIVagm and
SIVsmm could have led to the acquisition of SIVagm.Sab vpr by
the latter (Sharp et al., 1996; Hu et al., 2003). In agreement with
this, recombination events between those two viruses have been
shown before (Jin et al., 1994) and the habitats of African green
monkeys and sooty mangabeys are partly overlapping. As the Vpr
proteins of the HIV-2/SIVsmm/SIVmac and SIVrcm/SIVmnd-2
lineages are inactive against SAMHD1 (Lim et al., 2012) and as
this function was acquired by the other vpr genes before the birth
of vpx, it seems likely that the former Vpr proteins were never able
to antagonize SAMHD1. Therefore, the acquisition of vpr from
SIVagm would have been beneficial in this respect. Along these
lines, it has been shown that the Vpr protein of SIVagm.Ver is able
to antagonize a broad range of SAMHD1 proteins from primates
(Lim et al., 2012). It is tempting to speculate that this may also be
the case for SIVagm.Sab Vpr. This would favor the recombination
(rather than the duplication) hypothesis, but would need to be
assessed experimentally.
The rate of evolution of vpx seems to be slower than that of vpr,
as shown by shorter branch lengths in the vpx lineage compared to
the vpr one (see the HIV-2/SIVsmm/SIVmac lineage in Figure 5)
(Tristem et al., 1992). This could be explained by the fact that
vpx is overlapping with other genes to a greater degree than vpr,
inducing a stronger constraint. In HIV-1 HXB2 for instance, 28%
of the vpr gene is overlapping with other reading frames (vif and
tat), whereas in HIV-2 BEN, 50% of vpx is overlapping (with vpr).
A difference in selective pressures could also explain this disparity
in evolution rate.
SIVcpz, which gave rise to the four known groups of HIV-1
after cross-species transmissions, is the result of recombination
events between ancestors of SIVs from red-capped mangabeys
and Cercopithecus species such as greater spot-nosed, mus-
tached and mona monkeys (Bailes et al., 2003; Sharp and
Hahn, 2011). Each of these viruses has the ability to antagonize
SAMHD1 from the species they target (SIVrcm with vpx and
SIVgsn/SIVmus/SIVmon with vpr) (Lim et al., 2012). However,
this function was lost in SIVcpz (Etienne et al., 2013). As vpx from
SIVrcm was unable to antagonize chimpanzee SAMHD1 (Lim
et al., 2012), the loss of vpxmight have hadminimal consequences
for the transmission of SIV to chimpanzees. It was hypothesized
that the loss of vpx—vpr remained intact—led to the reconstruc-
tion of vif by overprinting and the acquisition of full antagonism
of APOBEC3 proteins from chimpanzee (Etienne et al., 2013).
One might speculate that evolution of vif to fully counteract
chimpanzee APOBEC3G was more important for SIVcpz than
evolution of vpx as a SAMHD1 antagonist.
Evolutionary analysis of SAMHD1 revealed strong signatures
of positive selection in the N- and C-terminal parts of the pro-
tein (Laguette et al., 2012; Lim et al., 2012), suggesting that
both termini may contribute to the interaction with Vpx. It has
been shown recently that the separation of the two clades of
vpx (HIV-2/SIVsmm/SIVmac and SIVrcm/SIVmnd-2) correlates
with the domain of SAMHD1 targeted by these Vpx proteins. Vpx
proteins from the HIV-2/SIVsmm/SIVmac lineage recognize the
C-terminal domain of SAMHD1 (Ahn et al., 2012; Fregoso et al.,
2013), whereas Vpx proteins from the SIVrcm/SIVmnd-2 lin-
eage interact with the N-terminal domain of SAMHD1 (Fregoso
et al., 2013; Wei et al., 2014). The model presented to explain
this involves the particular head-to-tail dimer conformation of
SAMHD1 and a Vpx (or Vpr) protein binding to both N-terminal
and C-terminal domains of SAMHD1 with a high affinity for
one of these domains and a lower affinity for the other. When
mutations occurring in SAMHD1 lead to a decreased affinity and
escape from Vpx, mutants of Vpx leading to higher affinity on
the other domain might be selected (Fregoso et al., 2013). This
evolutionary arms-race likely led to species specificity (Fregoso
et al., 2013; Wei et al., 2014) and emphasizes the importance of
the conservation of Vpx (Vpr) mediated SAMHD1 antagonism
for lentiviruses. In agreement with this notion, SAMHD1 antag-
onism is actively maintained in natural infections, as exemplified
by SIVagm vpr adaptations to SAMHD1 polymorphisms found
in the African green monkey population (Spragg and Emerman,
2013).
HIV-1, A PANDEMIC VIRUS LACKING THE X-TRAORDINARY
PROTEIN
Although essential for certain primate lentiviruses, it is some-
what surprising that the ability to antagonize SAMHD1, as
well as any other functions borne by vpx, were lost during the
genesis of SIVcpz (Etienne et al., 2013). They were dispens-
able for the establishment of SIVcpz in chimpanzees and its
cross-species transmission to humans, which gave rise to HIV-1.
Whereas the other potential functions of vpx might be pro-
vided by other genes in HIV-1/SIVcpz, it seems that HIV-1
does not need to antagonize SAMHD1 to replicate efficiently
in humans. It is still not understood why SAMHD1 antago-
nism is crucial in some primate lentiviruses but dispensable in
others. HIV-1 mainly targets cycling CD4+ T cells in which
dNTP concentrations are high (Diamond et al., 2004), hence
SAMHD1 antagonism may not be needed. Of note, HIV-1
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FIGURE 5 | Maximum likelihood phylogeny of primate lentiviruses vpr
and vpx genes. vpr are represented in blue and vpx in red. Branch lengths
represent nucleotide substitutions per site, as indicated in the scale. Branch
supports are indicated by one asterisk (≥90% confidence) or two asterisks
(≥99%). The tree was rooted using the midpoint rooting method.
Abbreviations: HIV, human immunodeficiency virus; SIV, simian
immunodeficiency virus; cpz, chimpanzee (Pan troglodytes); gor, gorilla
(Gorilla gorilla); stm, stump-tailed macaque (Macaca arctoides); smm, sooty
mangabey monkey (Cercocebus atys); mac, rhesus macaque (Macaca
mulatta); mne, pig-tailed macaque (Macaca nemestrina); rcm, red-capped
mangabey (Cercocebus torquatus); drl, drill monkey (Mandrillus leucophaeus);
mnd, mandrill (Mandrillus sphinx); lst, L’Hoest’s monkey (Cercopithecus
lhoesti); sun, sun-tailed monkey (Cercopithecus solatus); olc, olive Colobus
(Procolobus verus); gsn, greater spot-nosed monkey (Cercopithecus
nictitans); mus, mustached monkey (Cercopithecus cephus); mon, mona
monkey (Cercopithecus mona); tal, northern talapoins (Miopithecus
ogouensis); deb, De Brazza’s monkey (Cercopithecus neglectus); syk, Sykes’
monkey (Cercopithecus mitis); agm TAN, tantalus African green monkey
(Chlorocebus tantalus); agm VER, vervet African green monkey (Chlorocebus
pygerythrus); agm GRV, grivet African green monkey (Chlorocebus aethiops);
agm SAB, sabaeus African green monkey (Chlorocebus aethiops sabaeus);
col, guereza colobus monkey (Colobus guereza).
reverse transcriptase (RT) has a relatively high binding affin-
ity for dNTPs, as compared to MLV (Weiss et al., 2004), which
facilitates replication in cells with reduced dNTP content such
as MDMs (Diamond et al., 2004). In line with this, HIV-1
RT mutant V148I, which has reduced dNTP binding affinity
(Diamond et al., 2003, 2004), decreases HIV-1’s ability to infect
MDMs (Diamond et al., 2004; Lahouassa et al., 2012). Whether
the RTs of HIV-2/SIVsmm have lower dNTP binding affinities
than HIV-1 RT is currently unknown, but this could contribute
to their dependence upon vpx. Alternatively viruses coding vpx
might rely more on myeloid cell infection to disseminate in vivo
than the ones lacking this gene. Of note, most non-primate
lentiviruses, such as maedi-visna or caprine arthritis-encephalitis
virus, tend toward myeloid tropism (though the mechanisms
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used by these viruses to cope with low dNTP levels are currently
unknown).
It would be of major interest to determine whether there is a
connection between SAMHD1 degradation and an altered equi-
librium between pathogen replication and host survival. Indeed
primate lentiviruses able to antagonize SAMHD1 seem better
tolerated by their natural hosts. This is exemplified by the dif-
ference observed in pathogenicity between HIV-1 and SIVmnd-1
compared to HIV-2, SIVsmm and SIVmnd-2.
The in vitro infection of MDDCs with HIV-2 causes their
activation through detection of viral cDNA by the DNA sen-
sor cyclic GMP-APM synthase (cGAS) (Lahaye et al., 2013). In
contrast, HIV-1 is normally unable to infect MDDCs and there-
fore does not activate them (Manel et al., 2010). However, HIV-1
can be artificially rendered able to infect DCs through the provi-
sion of Vpx, leading to potent MDDC activation and secretion of
cytokines including type 1 IFN (Manel et al., 2010; Lahaye et al.,
2013). Under these artificial conditions HIV-1 seems to cause a
stronger MDDC activation than HIV-2 (Yu et al., 2013). This
strongly suggests that the absence of Vpx may actually be benefi-
cial for HIV-1 as this would help avoiding infection and activation
of DCs and therefore prevent initial innate (and then adaptive)
immune responses detrimental to the virus. This would not be
a unique example of a virus benefiting from limiting myeloid
cell tropism. Indeed mosquito-borne North American eastern
equine encephalitis virus (EEEV) is potently restricted by a spe-
cific miRNA in myeloid cells, whereas the sequence targeted by
this miRNA is crucial for mosquito vector infection (Trobaugh
et al., 2013). By limiting myeloid cell tropism and consequent
innate immunity induction, the restriction directly promotes
neurologic disease manifestations characteristic of EEEV infec-
tion in humans. In line with this, it is tempting to speculate that
HIV-2might be less pathogenic because it induces innate immune
responses, possibly through myeloid cell infection. However, vpx
isolated from viremic and long-term aviremic HIV-2 infected
individuals display similar abilities to antagonize SAMHD1 and
enhance virus infection (Yu et al., 2013), presumably reflecting
the complexity of viral pathogenesis.
Interestingly, there is some evidence that individuals present-
ing HIV-1/HIV-2 co-infections have better long-term outcomes
and slower progression to AIDS, compared to HIV-1 mono-
infected patients (Esbjornsson et al., 2012). HIV-2 co-infection
seems to protect from HIV-1 pathogenesis for a certain period of
time. It would be of high interest to understand the basis for this
and whether Vpx plays a role in it.
CONCLUSION
Vpx is a protein uniquely encoded by the HIV-2/SIVsmm and
SIVrcm/SIVmnd-2 lineages, which has the property to favor
myeloid cell infection through inducing the degradation of
SAMHD1. It is absolutely required for efficient HIV-2/SIVsmm
viral replication in vivo, suggesting an important role of myeloid
cells as target cells for these viruses and/or that additional roles,
such as APOBEC3A antagonism, may be important. In addition,
Vpx is able to render DCs more permissive to HIV-1 infec-
tion, and this may promote the induction of stronger innate
immune responses. These major findings might open the way for
the prospective development of novel HIV-1 vaccine and treat-
ment strategies based on the use of Vpx. In theory, treatment
with a vaccine using Vpx-VLPs may stimulate immune responses,
potentially leading to improved protection against (or control
of) HIV-1.
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